House Bill 7647
116th Congress(2019-2020)
To provide for a COVID-19-related delay regarding annual limitation on cost-sharing for group health plans and individual and small group health insurance coverage.
Introduced
Introduced in House on Jul 16, 2020
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
7647
Congress
116
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Donald McEachin
grade
Virginia
Arizona
Arizona
California
California
California
California
California
California
California
Delaware
Florida
Florida
Georgia
Illinois
Illinois
Illinois
Illinois
Indiana
Maryland
Massachusetts
Minnesota
Minnesota
Mississippi
New Hampshire
New Jersey
New Jersey
New Jersey
New York
New York
North Carolina
Oklahoma
Oregon
Pennsylvania
Texas
Texas
Virginia
No House votes have been held for this bill.
Summary
This bill delays until the first calendar year that is 12 months after the end of the COVID-19 (i.e., coronavirus disease 2019) public health emergency the application of the Centers for Medicare & Medicaid Services (CMS) rule dated May 14, 2020. That rule allows private health insurance plans to decide whether support provided by a prescription drug manufacturer to cover a patient's costs for a drug counts toward the patient's annual out-of-pocket limit. The bill requires enforcement of the previous rule, which allows plans to exclude drug manufacturer support from a patient's annual out-of-pocket limit only if a generic version of the drug is available.
July 16, 2020
07/16/2020
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Labor, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
07/16/2020
Referred to the Subcommittee on Health.
07/16/2020
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:45:55 PM